Wireva

Researchers revive idea that Alzheimer's begins with loss of specific brain neurons

A long-sidelined hypothesis holds that losing a particular group of brain cells drives Alzheimer's, challenging the field's dominant focus on amyloid plaques.

Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation
Experimental Alzheimer’s drug repairs DNA damage and reduces brain inflammation
Vertenflow · Public domain · rights

A theory that Alzheimer's disease is driven by the death of specific nerve cells, rather than by the protein clumps that have dominated the field for decades, is drawing renewed attention from researchers. The idea had largely fallen out of favor, but a small and growing group of scientists is now re-examining whether neuron loss is a primary cause of the disease rather than a downstream effect.

For most of the past several decades, the leading explanation for Alzheimer's has centered on amyloid plaques, the sticky deposits of protein that accumulate between brain cells in people with the disease. That focus has shaped drug development and research funding. The revived hypothesis instead points to cholinergic neurons, cells in the basal forebrain that rely on the chemical messenger acetylcholine. The loss of these cells has been linked to memory and cognitive decline, and some researchers argue it may come first.

The evidence so far comes mainly from postmortem brain tissue, which allows scientists to compare the brains of people who had Alzheimer's with those who did not, and from animal models that can be studied more directly. Those lines of work suggest a connection between the loss of these neurons and the symptoms of the disease, but they do not settle the central question of sequence: whether the cells die because of plaques, or whether their loss helps set the disease in motion.

That open question carries practical weight. If neuron loss is an early driver, treatments aimed at protecting or replacing these cells could in principle slow the disease. Researchers have not yet determined whether targeting these cells would change its course, and any implications for drug development remain speculative. The body of research supporting the hypothesis is still small and ongoing, and the wider field continues to debate how much weight it deserves.